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A new approach to obtain pure and 
active proteins from Lactococcus 
lactis protein aggregates
L. Gifre-Renom1, O. Cano-Garrido2,3,4, F. Fàbregas1, R. Roca-Pinilla1, J. Seras-Franzoso2,3,4,6, 
N. Ferrer-Miralles2,3,4, A. Villaverde2,3,4, À. Bach1,5, M. Devant1, A. Arís1 & E. Garcia-Fruitós  1
The production of pure and soluble proteins is a complex, protein-dependent and time-consuming 
process, in particular for those prone-to-aggregate and/or difficult-to-purify. Although Escherichia coli is 
widely used for protein production, recombinant products must be co-purified through costly processes 
to remove lipopolysaccharide (LPS) and minimize adverse effects in the target organism. Interestingly, 
Lactococcus lactis, which does not contain LPS, could be a promising alternative for the production 
of relevant proteins. However, to date, there is no universal strategy to produce and purify any 
recombinant protein, being still a protein-specific process. In this context and considering that L. lactis 
is also able to form functional protein aggregates under overproduction conditions, we explored the use 
of these aggregates as an alternative source of soluble proteins. In this study, we developed a widely 
applicable and economically affordable protocol to extract functional proteins from these nanoclusters. 
For that, two model proteins were used: mammary serum amyloid A3 (M-SAA3) and metalloproteinase 
9 (MMP-9), a difficult-to-purify and a prone-to-aggregate protein, respectively. The results show that 
it is possible to obtain highly pure, soluble, LPS-free and active recombinant proteins from L. lactis 
aggregates through a cost-effective and simple protocol with special relevance for difficult-to-purify or 
highly aggregated proteins.
Recombinant proteins represent a growing market and their applications are numerous for human medicine1 
and animal health and production2. To date, more than 400 recombinant proteins have been approved for human 
medicine and this number is expected to rise in the coming years1,3. Nowadays recombinant products can be 
based on naturally occurring biomolecules, but they can also be de novo designed proteins or even modular 
proteins with improved properties. However, proteins of interest are labile macromolecules and, in many cases, 
they are also prone-to-aggregate. In this context, the process to obtain recombinant soluble proteins is, in many 
cases, complex and time-consuming. Besides, nowadays there is no well-established universal protocol for the 
successful production and purification of recombinant proteins. All this has lead the research community to 
develop specific and in many cases cumbersome, protein-dependent production and purification strategies to 
reach the desired product. Escherichia coli has been, by far, the most widely used bacterium for recombinant pro-
tein production purposes. However, although the wide catalogue of available tools for protein production in this 
expression system, the presence of lipopolysaccharide (LPS) in its outer membrane limits the in vivo applicability 
of the recombinant product obtained from this Gram-negative bacterium. The presence of LPS in the recombi-
nant product can trigger non-desired inflammatory responses once the protein has been administered, making 
the addition of extra purification steps essential to completely remove LPS from the recombinant product4–6.
In the last decades, the use of alternative bacterial expression systems lacking endotoxins has significantly 
increased7. Among them, the Gram-positive Lactococcus lactis has been vastly studied7–10. This bacterium has 
been classified as a generally recognized as safe (GRAS) microorganism by the Food and Drug Administration 
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(FDA) and thus, it represents a promising alternative to E. coli for recombinant protein production purposes10. 
Thus far, L. lactis has essentially been explored as a microbial cell factory for the production of soluble proteins, 
either intracellularly or secreted to the media7,8,11–17. However, recent studies show that this GRAS expression 
system does not differ from others in its capacity to form protein aggregates under overexpression conditions9,18. 
Different heterologous proteins produced in L. lactis have been found not only in their soluble form, but also 
as protein aggregates in the bacterial cytoplasm19. L. lactis aggregates (or inclusion bodies -IBs-), as it occurs 
with those found in other recombinant expression systems, are fully functional protein nanoclusters that are 
spontaneously formed under overproduction conditions9,18,19. The formation of such protein deposits is par-
ticularly relevant for those proteins difficult-to-purify and/or prone-to-aggregate9,18. In these cases, although the 
recombinant protein is free of LPS, the strategy used to produce and purify each specific protein is still largely 
protein-specific, as it occurs in other expression systems. Since these aggregates might be an alternative source of 
difficult-to-obtain proteins in L. lactis and considering the need to develop a universal protocol for the production 
and purification of LPS-free recombinant proteins, the objective of this study was to develop a broad-application 
strategy to extract functional protein from L. lactis aggregates. For that, two proteins have been used as model 
proteins in this work: mammary serum amyloid A3 (M-SAA3), a difficult-to-express protein20,21 and metallo-
proteinase 9 (MMP-9), which is prone-to-aggregate18. M-SAA3 is an acute phase protein that participates in the 
innate immune response of the mammary gland. On the other hand, MMP-9 is an enzyme that degrades the 
extracellular matrix and is involved in the immune response and tissue remodeling.
Results
Characterization of the M-SAA3 production in L. lactis. In a first approach to evaluate the production 
profile of M-SAA3 in L. lactis, the production kinetics of this model protein was analyzed at 30 °C at different 
times post-induction. The separation of the soluble and the insoluble fractions of the cell lysate indicated that 
M-SAA3 was mainly produced in the soluble form (65–80%) in L. lactis cytoplasm, although protein aggregates 
(IBs) were also formed (Fig. 1a). Along time, there was a significant increase in the percentage of the aggregated 
M-SAA3 at 1.5, 2 and 3 h compared with 1 h post-induction (P = 0.002) (Fig. 1a). However, the percentage of 
Figure 1. Productions of M-SAA3 in L. lactis after nisin induction under different conditions. (a) Kinetics for 
the produced M-SAA3 at 1, 1.5, 2 and 3 h post-induction at 30 °C. Different letters depict differences between 
production times (P = 0.002). The bars indicate the percentage of soluble (white) and of aggregated M-SAA3 
(black). Error bars indicate the standard error (SE). Values for the % of aggregation are indicated on top of each 
bar. (b) Productions at different temperatures: 30, 20 and 16 °C. The bars indicate the percentage of soluble 
(white) and of aggregated M-SAA3 (black). Error bars indicate the standard error (SE). (c) Productions at 
different nisin concentrations, along 1.5 h and at 30 °C. The light grey line indicates L. lactis growth rates (final 
OD/OD at induction). The greatest production values of M-SAA3 were set as 100%. Different letters depict 
differences between nisin concentrations (P = 0.002) and growth rates (P = 0.041). Error bars indicate the 
standard error (SE).
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aggregation did not change when using different growing temperatures (∼36% at 30 °C and 20 °C and 39.8% at 
16 °C) (Fig. 1b).
The total amount of M-SAA3 produced improved by increasing the inducer concentration. Specifically, sig-
nificant differences were observed using concentrations of 2.5, 5, 12.5 and 25 ng/ml nisin (P = 0.002) (Fig. 1c). 
Interestingly, L. lactis growth rate was lower in the last four nisin concentrations tested (P = 0.041), where the 
M-SAA3 production was enhanced, which indicates that growth rate can be negatively affected either by high 
nisin concentrations or by high production of M-SAA3 (Fig. 1c).
Thus, after this first screening, the production of soluble M-SAA3 at 30 °C at 1.5 h using 12.5 ng/ml nisin was 
established as the optimal condition.
M-SAA3 purification from the soluble fraction. As a starting point, the production and purification of 
soluble M-SAA3 following a standard protocol was assessed. For that, 1 l of L. lactis was grown at 30 °C and, after 
that, a purification trial using a standard immobilized metal affinity chromatography (IMAC) purification proto-
col for the isolation of cytoplasmic soluble proteins was performed (Table 1, condition 1). Under this condition, a 
large protein loss was observed during the purification process (Fig. 2, condition 1). Moreover, the eluted protein 
had low purity, being the presence of two proteins of around 50 and 75 kDa especially relevant (Fig. 2, condition 1). 
MALDI-TOF analyses revealed that these two main impurities were proteins from host bacteria and corresponded 
to L. lactis elongation factor TU (pI = 4.89; 43.2 kDa) and L. lactis elongation factor G (pI = 4.75; 77.9 kDa).
Aiming to optimize the purification process of the soluble protein M-SAA3, eight different strategies combin-
ing different imidazole concentrations and/or the addition of detergents or other solubility enhancers were tested 
(Table 1, conditions 2–8). In some cases, a cation-exchange step was added after the IMAC purification (Table 1, 
conditions 5 and 8) in order to increase the purity of the recombinant product. Some strategies such as conditions 
3, 6, 7 and 8 reduced the protein loss, being this improvement particularly relevant for the condition 8. However, 
despite a substantial decrease in the amount of unbound protein, none of these strategies (conditions 3, 6, 7 and 
8) significantly increased the purity of the final product. Besides, the incorporation of a purification step using 
a cation-exchange approach did not improve the result of the whole purification process. Thus, in general terms 
we can conclude that none of the tested strategies allowed to obtain highly pure M-SAA3 through an efficient 
purification process (Fig. 2).
Solubilization and purification of M-SAA3 aggregates. Once proven that soluble M-SAA3 produced 
in L. lactis cannot be successfully purified using conventional strategies under a trial-and-error process, we eval-
uated whether the extraction of soluble M-SAA3 from L. lactis aggregates could be an alternative. Considering 
that L. lactis aggregates are formed by biologically active proteins, a new, simple and non-denaturing protocol for 
the isolation of soluble and functional proteins using these bacterial aggregates as protein source was developed. 
Specifically, different washing steps with the use of a mild detergent for the efficient solubilization of M-SAA3 IBs, 
without using any denaturing agent, were combined (Fig. 3). Importantly, we proved that is possible not only to 
isolate soluble M-SAA3 protein from L. lactis aggregates, but also that the purified product has a high degree of 
purity (>98.5%) (Fig. 4a). In this context, it is important to emphasize that the recombinant product was purified 
in absence of the two major impurities (L. lactis elongation factor TU and elongation factor G) found in most 
of the conditions tested for the purification of soluble protein (Table 1). In the elution profile of the purification 
1 2 3 4 5 6 7 8
Binding buffer (BB) 20 mM Tris pH = 8, 500 mM NaCl, 20 mM IMZ
20 mM 
Phosp. 
pH = 8, 
1.5 M NaCl, 
50 mM 
IMZ
20 mM Phosp. 
pH = 8, 500 mM 
NaCl, 20 mM IMZ
Elution buffer (EB)
20 mM Tris 
pH = 8, 
500 mM 
NaCl, 
500 mM 
IMZ
20 mM Tris 
pH = 8, 
500 mM 
NaCl, 2 M 
IMZ
20 mM Tris pH = 8, 500 mM NaCl, 1 M IMZ
20 mM 
Phosp. 
pH = 8, 
1.5 M NaCl, 
1 M IMZ
20 mM Phosp. 
pH = 8, 500 mM 
NaCl, 1 M IMZ
Solubility Enhancer . .
0.5% 
Triton 
X-100 
(toxic)
5% Glycerol 10% Glycerol 0.5% Tween-20
Protein loss +++ +++ ++ +++ +++ ++ ++ −
Cation Exchange . . . .
BB: 20 mM 
Tris pH = 7
EB: 20 mM 
Tris pH = 7, 
1 M NaCl
. .
BB: 20 mM Tris 
pH = 8
EB: 20 mM Tris 
pH = 8, 1 M NaCl
Purity (%) 13.8 12.4 54 15.2 30.4 20.8 ND ND
Main Impurities 50–75 kDa 50–75 kDa 75 kDa 50 kDa 50 kDa 50–75 kDa 50–75 kDa 50–75 kDa
Table 1. Tested conditions in the process to optimize the purification of the soluble M-SAA3. IMZ: imidazole; 
Phosp.: phosphate buffer; pI: Isoelectric point; ND: non-detectable.
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of the solubilized M-SAA3, only two bands of 13–15 kDa and 26–30 kDa were detected, which corresponded to 
M-SAA3 monomer and dimer, respectively (Fig. 4a).
Activity of the solubilized and purified M-SAA3. An in vitro assay using bovine epithelial cells from the 
mammary gland was conducted to test the activity of the M-SAA3 obtained through the new purification method. 
The results of this assay showed that the M-SAA3 was fully active and a dose-dependent effect could be observed 
on the stimulation of interleukin 8 (CXCL8) expression (Fig. 5) after M-SAA3 treatment21. Specifically, a 1.6-fold 
increase of CXCL8 expression compared with the PBS treatment was obtained by adding 9 µg/ml of M-SAA3 to 
the cells, whereas a 3-fold increase was noted for the treatment with 90 µg/ml of M-SAA3 (P < 0.0001).
IB solubilization of prone-to-aggregate proteins. To determine the efficacy of the new protocol with 
other difficult proteins, we assessed its effectiveness with a protein with a high tendency to aggregate, namely 
MMP-9. The aggregation rate in L. lactis of this protein has already been described, with reported values up to 
100%18. Thus, we produced and purified MMP-9 aggregates, which were solubilized following the described pro-
tocol (Fig. 3). Again, soluble and highly pure proteins were obtained with this novel protocol. Specifically, a purity 
of 99% was observed by Coomassie staining for MMP-9 (Fig. 4b) and the activity of the soluble metalloproteinase 
obtained through the new method was tested. Specifically, the activity was tested by zymography, observing that 
soluble MMP-9 was active following a dose-dependent effect (Fig. 6).
Discussion
The production and purification of recombinant proteins is often a difficult and product-dependent process. The 
M-SAA3 is just one example amongst many other difficult-to-produce and difficult-to-purify proteins. Previous 
reports have shown that its production requires a difficult and a time-consuming process20–22. Moreover, results 
shown in this work reveal that none of the commonly used strategies to improve protein production and purifica-
tion can be used for the isolation of M-SAA3 in its soluble form, using L. lactis as an intracytoplasmic expression 
system (Fig. 2). Another example of difficult proteins are MMPs, which have previously shown to have a strong 
tendency to aggregate in both E. coli23–25 and L. lactis18, reaching levels of up to 100% aggregation. Under these 
situations, which are common under recombinant production conditions, protein production and purification 
from the soluble fraction can become a long and unsuccessful trial-and-error process and alternative approaches 
are needed.
IBs are protein aggregates produced in recombinant bacteria under conditions of protein overproduction26,27. 
Their formation has been mainly described in E. coli cytoplasm, but increasing evidence shows that aggregation 
under these conditions occurs in different expression systems, including L. lactis28. These aggregates are com-
posed mainly by the overexpressed protein in its active form and they are formed through a specific process29,30, 
which means that they might drag just few proteins from the cell cytoplasm. Thus, due to their special features, 
IBs represent an appealing source of functional recombinant protein31. However, traditionally, the recovery of 
proteins from IBs produced by E. coli has been done using a two-step process, including a hard denaturation step 
(using agents like urea or guanidine hydrochloride) followed by, an often, non-efficient refolding process32,33. This 
Figure 2. Protein gels for the soluble M-SAA3 IMAC purifications at different conditions (1, 3, 5, 6 and 8 in 
Table 1). Lane 1: flow through (FT) or non-bound protein, lane 2: eluted protein (EP). The eluted M-SAA3 
is observed by Western blot in two bands, a monomer at 13–15 kDa and a dimer at 26–30 kDa (indicated by 
arrows). The obtained purities can be observed by Coomassie staining (* and ϕ indicate the main impurities). 
High-contrast was applied when necessary -only in Coomassie lanes- to allow a better display of the bands. 
Complete and original gels and blots for each condition can be found in the supplementary material 
(Supplementary Fig. 1).
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aggressive treatment disregards the IB nature and protein comprised in these aggregates is completely denatured. 
Thus, since these aggregates are formed by functional recombinant protein, the use of mild protocols to extract 
properly folded soluble proteins from IBs could be a promising strategy to avoid the use of denaturing agents. In 
this context, this approach has already been proven in E. coli32,34, but no procedure has been developed thus far 
for the isolation of soluble and LPS-free proteins using L. lactis aggregates14,18. In the present work, we have devel-
oped a novel and straightforward procedure (Fig. 3) to obtain soluble, pure and biologically active proteins from 
L. lactis aggregates. Since the formation of MMP-9 IBs by L. lactis has been recently described18 and the aggre-
gation rates of the M-SAA3 can be increased by prolonging the production incubation time (Fig. 1a), we have 
used these proteins as models to evaluate L. lactis aggregates as a potential source of difficult proteins. Specifically, 
we have proven that it can be successfully applied with both difficult-to-express and difficult-to-purify proteins 
(Figs 4–6). On the one hand, we have shown that protein purity levels increase (Fig. 4) and the recovered protein 
is biologically active (Figs 5 and 6). Moreover, unlike protocols developed for the isolation of soluble proteins 
from E. coli IBs, this new procedure allows to isolate LPS-free proteins. Altogether gives consistency to the new 
method that can be applied as a unique approach to obtain pure yields of difficult-to-isolate proteins from bac-
terial aggregates in a soluble format and free of endotoxins. Thus, this approach is an appealing alternative to 
the extracytoplasmatic production35 for the isolation of soluble proteins that are mainly produced as protein 
aggregates.
Conclusions
We have developed a new approach to obtain prone-to-aggregate and difficult-to-purify proteins in its soluble 
form using L. lactis as expression system. For the first time, we have proven that it is possible to use L. lactis aggre-
gates as a source of fully functional proteins free of endotoxins. For that we have developed a protocol widely 
applicable for proteins that cannot be obtained through standard procedures without the need to add denaturing 
Figure 3. Schematic protocol for the solubilization of the M-SAA3 IBs produced in L lactis.
www.nature.com/scientificreports/
6Scientific REPORTS |  (2018) 8:13917  | DOI:10.1038/s41598-018-32213-8
agents. The developed method represents an economical alternative that opens the door to the production of new 
recombinant proteins that, to date, could not be obtained.
Methods
Bacterial strains and plasmids. Lactococcus lactis subsp. cremoris NZ900036 and NZ9000 clpP− htrA− 
(clpP-htrA; erythromycin resistant (EmR))37,38 (kindly provided by INRA, Jouy-en-Josas, France; patent n° 
EP1141337B1) strains and the sequence of two proteins, the catalytic domain of bovine metalloproteinase 
9 (MMP-9)18 and the goat mammary serum amyloid A3 (M-SAA3)21, were used in this study. Each protein 
sequence was flanked by NcoI and XbaI restriction sites and C-terminally fused to a His-tag for purification 
and quantification purposes. All genes were ligated into the chloramphenicol resistant (CmR) pNZ8148 plas-
mid (MoBiTech). The plasmid pNZ8148:SAA3 was transformed into electrocompetent L. lactis NZ9000, while 
Figure 4. IMAC purification of the solubilized aggregates produced in L. lactis. In the left side, the 
chromatograms of the M-SAA3 (a) and MMP-9 (b) elutions. In grey, the selected fractions of the eluted 
proteins. In the right side, Western Blot and Coomassie staining for each eluted protein (EP) and flow through 
(FT). The arrows indicate the correspondent bands for each protein -the M-SAA3 (a) appears in a monomeric 
and a dimeric form, whereas MMP-9 (b) appears mainly as monomers-. Complete gels and blots can be found 
in the supplementary material (Supplementary Fig. 2).
Figure 5. CXCL8 gene expression by bovine epithelial cells from the mammary gland with solubilized and 
purified M-SAA3, obtained from L. lactis aggregates. CXCL8 gene expression using 9 µg/ml and 90 µg/ml dose, 
using PBS as a control. Different letters depict differences between treatments (P < 0.0001). Error bars indicate 
the standard error (SE).
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pNZ8148:MMP-9 was transformed in L. lactis clpP-htrA. For electroporation, a Gene Pulser (Bio-rad) at 2500 V, 
200 Ω and 25 µF was used as detailed by Cano-Garrido et al.18.
M-SAA3 protein production. L. lactis NZ9000/pNZ8148:SAA3 plasmid was grown overnight (O/N) at 
30 °C in GM17 with 5 µg/ml Cm for plasmid maintenance. The O/N cultures were inoculated in fresh GM17 with 
Cm at an initial optical density at 600 nm (OD600) of 0.1. When cultures reached an OD600 = 0.4–0.6, the recom-
binant protein expression was induced with 12.5 ng/ml nisin.
Culture samples of 25 ml were taken and centrifuged (6,000 × g, 15 min, 4 °C) at 0, 1, 1.5, 2 and 3 h 
post-induction for a protein kinetics analysis. Samples for a temperature-effect analysis were taken at 0 and 3 h 
post-induction from cultures grown at 30 °C and at 0 and 16 h post-induction from cultures grown at 20 and 
16 °C. The inductor concentration-effect analysis was assessed by samples taken at 0 and 3 h post-induction with 
seven different nisin concentrations (0.625, 1.25, 2.5, 5, 12.5 and 25 ng/ml) in cultures grown at 30 °C. All the 
experiments were run in triplicate.
In all cases, pellets were resuspended in 500 µl PBS with an EDTA-free protease inhibitor cocktail (Roche) 
and bacteria were disrupted by sonication. Each sample was ice-coated and sonicated with 2 cycles of 1.5 min 
(0.5 sec cycles at 10% amplitude). The soluble and the insoluble protein fractions were separated by centrifugation 
at 15,000 × g for 15 min at 4 °C and the insoluble fraction was resuspended in the same buffer at the same initial 
volume.
Protein determination. The soluble and the insoluble protein fractions were analyzed by 15% denatur-
ing sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). All samples were resuspended 
with Laemmli loading buffer (100 mM Tris base, 8% glycerol, 55 mM SDS, 4% β-mercaptoethanol, 1.6 M urea). 
Soluble fractions were boiled for 5 min and insoluble fractions for 40 min before electrophoresis. Protein bands 
were electroblotted into PVDF membranes at constant 250 mA and 100 V for 1 h, followed by a blocking step 
with BSA O/N at 4 °C (5% BSA in TBST buffer: 10 mM Tris, 150 mM NaCl, 0.05% Tween 20). Anti poly-histidine 
(GE Healthcare; mouse) was used as the primary antibody at a 1/1,000 dilution in BSA-TBST buffer, in which 
membranes were incubated along 2 h at room temperature (RT), followed by 3 washes in TBST buffer. Then 
membranes were incubated in a 1/20,000 dilution in TBST of an anti-mouse IgG-alkaline phosphatase (Sigma), 
used as secondary antibody, along 1 h at RT followed by 3 washes in TBST buffer. Protein bands were developed 
after adding the alkaline phosphatase substrate solution NBT/BCIP (Thermo Scientific). Bands were quantified 
with a standard curve of T22-GFP-H639 and densitometry analyses with ImageJ software. The M-SAA3 aggre-
gation rate (insoluble protein/total protein) in L. lactis was calculated for both the kinetic and the temperature 
experiments.
Production and purification of the M-SAA3 from the soluble fraction. Cultures of 1 l of the 
M-SAA3-producer L. lactis were grown at 30 °C and induced with nisin at an OD600 = 0.4–0.6, as previously 
described14. The whole volume was recovered after 1.5 h of production and centrifuged at 5,000 x g for 15 min at 
4 °C. Pellets from 500 ml of culture were suspended in 30 ml of the binding buffer (20 mM Tris pH = 8, 500 mM 
NaCl, 20 mM imidazole) with an EDTA-free protease inhibitor cocktail (Roche). Bacteria were mechanically 
Figure 6. Zymography of MMP-9. Gelatin degradation can be observed using three different amounts of the 
solubilized MMP-9. Line 1: standard; line 2–4: different amounts of soluble MMP-9. The molecular weight of 
the solubilized MMP-9 (catalytic domain) is 39 kDa.
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disrupted by French Press (Thermo FA-078A) with 4 cycles at 1,500 psi in ice coating. Cell lysates were cen-
trifuged at 15,000 × g for 45 min and the M-SAA3 in the soluble fraction was purified by Immobilized Metal 
Affinity Chromatography (IMAC) in an ÄKTA purifier FPLC (GE Healthcare) using 5 ml HiTrap Chelating HP 
columns (GE Healthcare).
Optimization of the purification process of the soluble M-SAA3. Eight different purification exper-
iments were run to optimize the M-SAA3 final purity. Different imidazole concentrations (500 mM, 1 M and 2 M) 
were used in the elution buffer and none or different solubility enhancers were added to both the binding and 
the elution buffers (Triton X-100, glycerol, or Tween 20). Also, changes in the binding buffer were conducted: 
an increase of the imidazole concentration from 20 to 50 mM, a replacement of the Tris buffer for a phosphate 
buffer and an increase of the NaCl concentration from 500 mM to 1.5 M. All the tested combinations are detailed 
in Table 1.
The eluted peaks were dialyzed in PBS O/N, at 4 °C and with gentle agitation, unless a cation-exchange puri-
fication was scheduled. Cation-exchange chromatography was conducted in experiments 5 and 8 (see Table 1). 
The peaks obtained by the IMAC purification were dialyzed in 20 mM Tris pH = 7 in experiment 5, or in 20 mM 
phosphate buffer pH = 8 in experiment 8 (M-SAA3 isoelectric point is 8.67). In both cases, the dialyzed peaks 
were loaded in a negatively charged 1 ml SP FF column (GE Healthcare) and M-SAA3 was eluted by an increasing 
linear NaCl gradient to 1 M final concentration. Eluted samples were dialyzed in PBS as previously described.
The recovering efficiency and the purity of the eluted samples were determined by Western blot, as previously 
described14 and by Coomassie staining.
Solubilization of M-SAA3 and MMP-9 from protein aggregates. Five liters of M-SAA3 were pro-
duced in L. lactis NZ9000 and 2 l of MMP-9 were produced in L. lactis clpP-htrA. In these cases, inductions 
were conducted for 3 h. The whole volumes were centrifuged at 6,000 x g and the pellets were resuspended in 
lysis buffer (20 mM Tris, 500 mM NaCl, 20 mM imidazole, 10% glycerol) in presence of protease inhibitors and 
in a ratio of 500:30 (ml:ml, culture:buffer). Samples were subjected to 4 rounds of French Press disruption at 
1,500 psi, intercalated by a minimum of 5 min repose in ice. After that, 0.05 mg/ml lysozyme was added and 
samples were incubated for 2 h at 250 rpm and 37 °C. Protein pellets were recovered and washed twice with 
distilled water. Pellets were weighted and solubilized in 0.2% N-lauroyl sarcosine in Tris solution at a ratio 1:40 
(g:ml) as described by Peternel et al.34 and adding protease inhibitors. The mixture was incubated O/N at 4 °C in 
agitation and the supernatant was recovered through centrifugation at 15,000 × g for 45 min at 4 °C for further 
purification.
Purification of the solubilized M-SAA3 and MMP-9. NaCl and imidazole were added to the solubilized 
proteins to equilibrate the samples with the binding buffer composition and IMAC purification was carried as 
previously described. Both the binding and the elution buffer contained 0.2% N-lauroyl sarcosine and the final 
imidazole concentration in the elution buffer was 1 M for the M-SAA3 and 500 mM for the MMP-9. The selected 
fractions were dialyzed in PBS O/N at 4 °C and with gentle agitation. The amount of purified protein was deter-
mined by Bradford’s assay40 and the integrity of the protein analyzed by SDS-PAGE.
Identification of the main contaminating proteins. The main contaminating bands were cut and 
sequenced by MALDI-TOF in the Servei de Proteomica i Biologia Estructural (sePBioEs, Autonomous University 
of Barcelona).
Activity of the solubilized M-SAA3. Mammary epithelial cells from primary cultures were obtained as 
described elsewhere21 and seeded in 24-well plates at 44,000 cells/well. After 24 h incubation at 37 °C and 5% CO2, 
wells were washed twice with warm PBS and 500 μl PBS or two doses (9 µg and 90 µg in 500 μl of PBS) of the sol-
ubilized and purified M-SAA3 were added to each well containing 500 μl of DMEM/F‐12 medium with 8 μg/ml 
bovine insulin and 50 μg/ml hydrocortisone by sextuplicate. After 3 h of incubation at 37 °C, 5% CO2, cells were 
gently washed with PBS and 500 μl of Trizol reagent (Thermo Fisher Scientific) were added to each well to collect 
and lysate the cells. The extraction of RNA was performed using the Trizol reagent (Thermo Fisher Scientific) and 
it was processed for qPCR analyses of CXCL8 expression as described previously21. Relative gene expression was 
calculated using the 2∆Ct method with ACTB as reference gene.
Activity of the solubilized MMP-9. MMP enzymatic activities were determined by zymography using 
a 10% SDS-PAGE gel with 1% gelatin under non-denaturing conditions. After that, the gel was incubated 
with developing buffer and dyed with Coomassie as detailed by Cano-Garrido et al.18. Densitometry analyses 
of the bands were performed with the Image J software. The standard (kindly provided by the Laboratory of 
Immunobiology of the Rega Institute for Medical Research, KU Leuven, Belgium) corresponds to a mixture of 
purified monomeric MMP-9, multimeric MMP-9 and a mutant MMP-9 with a domain deletion41. The enzyme 
precursors, proMMP-9, are present in this standard.
Statistical analysis. All data were analyzed using a mixed-effects model that accounted for the random 
effects of replicate (n = 3) and the fixed effects of treatment and/or time of sampling (JMP, SAS Institute Inc.). 
Sampling time entered the model as a repeated measure using an autoregressive covariance matrix. When more 
than 2 means were compared, differences were established using the Tukey’s multiple mean separation test. Data 
were previously transformed to achieve a normal distribution when necessary. Results are expressed as the means 
of non-transformed data ± standard error of the mean (SEM).
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Data Availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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